This bill aims to prohibit pharmaceutical manufacturers and wholesale drug distributors from interfering in contracts between 340B entities and pharmacies. It amends existing law to include new provisions that make it unlawful for these entities to deny, restrict, or prohibit the acquisition or delivery of 340B drugs to authorized locations, unless such actions are mandated by federal law. Additionally, the bill specifies that manufacturers and distributors cannot require 340B entities or pharmacies to submit claims or utilization data as a condition for acquiring or receiving 340B drugs, again unless required by federal law.

Furthermore, the bill introduces penalties for violations, categorizing offenses based on the monetary value involved, with penalties ranging from Class 1 misdemeanors to Class 5 felonies. It also allows 340B entities or pharmacies to file civil actions against violators, seeking injunctive relief, damages, and attorney fees. The bill includes definitions for key terms such as "pharmaceutical manufacturer," "pharmacy," "340B drug," and "340B entity," ensuring clarity in its application.

Statutes affected:
Introduced, 01/30/2025: 37-24-6